Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives

Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of the time course of drug effects resulting from a certain dosing regimen. PK/PD-modeling approaches can basically be distinguished by four major attributes. The first characterizes the link between measured drug concentration and the response system, direct link versus indirect link. The second considers how the response system relates effect site concentration to the observed outcome, direct versus indirect response. The third regards what clinically or experimentally assessed information is used to establish the link between concentration and effect, hard link versus soft link. And the fourth considers the time dependency of pharmacodynamic model parameters, distinguishing between time-variant versus time-invariant. Application of PK/PD-modeling concepts has been identified as potentially beneficial in all phases of preclinical and clinical drug development. Although today predominantly limited to research, broader application of PK/PD-concepts in clinical therapy will provide a more rational basis for patient-specific dosage individualization and may thus guide applied pharmacotherapy to a higher level of performance.

[1]  L B Sheiner,et al.  Pharmacokinetic and pharmacodynamic modeling in vivo. , 1981, Critical reviews in bioengineering.

[2]  M W Fischman,et al.  Kinetics of cocaine distribution, elimination, and chronotropic effects , 1985, Clinical pharmacology and therapeutics.

[3]  C. T. Viswanathan,et al.  Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.

[4]  S. Tunn,et al.  Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids , 1993, Journal of clinical pharmacology.

[5]  R B Smith,et al.  Pharmacodynamic Modelling , 1991, Clinical pharmacokinetics.

[6]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.

[7]  B. Plaud,et al.  Population pharmacokinetic‐pharmacodynamic analysis of fluindione in patients , 1998, Clinical pharmacology and therapeutics.

[8]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[9]  Richard P. Lewis,et al.  Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.

[11]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies , 1992 .

[12]  M Wakelkamp,et al.  The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. , 1998, British journal of clinical pharmacology.

[13]  G Levy,et al.  Kinetics of drug action: an overview. , 1986, The Journal of allergy and clinical immunology.

[14]  Richard R. Almon,et al.  Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[15]  H. Derendorf,et al.  Handbook of Pharmacokinetic/Pharmacodynamic Correlation , 1995 .

[16]  G. Segre,et al.  Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.

[17]  W. Colburn Selecting and Validating Biologic Markers for Drug Development , 1997, Journal of clinical pharmacology.

[18]  L B Sheiner,et al.  Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.

[19]  C. van Boxtel,et al.  Kinetics of drug effects in man. , 1988, Therapeutic drug monitoring.

[20]  W. Colburn Pharmacokinetic/pharmacodynamic modeling: What it is! , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  L B Sheiner,et al.  Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.

[22]  G. Levy Kinetics of drug action in man. , 2009, Acta pharmacologica et toxicologica.

[23]  D. Shindler,et al.  A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects , 1997, Journal of clinical pharmacology.

[24]  W. Colburn,et al.  Surrogate Biochemical Markers: Precise Measurement for Strategic Drug and Biologics Development , 1995, Journal of clinical pharmacology.

[25]  W. Colburn,et al.  Efficacy Measures: Surrogates or Clinical Outcomes? , 1996, Journal of clinical pharmacology.

[26]  G Levy,et al.  Multicompartment pharmacokinetic models and pharmacologic effects. , 1969, Journal of pharmaceutical sciences.

[27]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[28]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[29]  G Levy,et al.  Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.

[30]  France Mentré,et al.  The Use of Population Pharmacokinetics in Drug Development , 1996, Clinical pharmacokinetics.

[31]  Johan Gabrielsson,et al.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration , 1996, Clinical pharmacology and therapeutics.

[32]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[33]  Wayne A. Colburn,et al.  Simultaneous pharmacokinetic and pharmacodynamic modeling , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[34]  W. Gentry,et al.  A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[35]  E. Chan,et al.  Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model , 1994, Clinical pharmacology and therapeutics.

[36]  M Davidian,et al.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. , 1994, Biometrics.

[37]  R. Koopmans,et al.  Pharmacodynamic modelling of the drug-induced downregulation of a β2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone , 2004, European Journal of Clinical Pharmacology.

[38]  H. Möllmann,et al.  Pharmacokinetic/Dynamic Correlation of Pulmonary and Cardiac Effects of Fenoterol in Asthmatic Patients After Different Routes of Administration , 1992, Pharmaceutical Research.

[39]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[40]  A. Racine‐Poon,et al.  Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti‐immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis , 1997, Clinical pharmacology and therapeutics.

[41]  L. Sheiner,et al.  Further notes on physiologic indirect response models , 1995, Clinical pharmacology and therapeutics.

[42]  John Anthony Bauer,et al.  Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.

[43]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[44]  H. Schwilden,et al.  Pharmacokinetic-pharmacodynamic modelling of the EEG effects of Ro 48-6791, a new short-acting benzodiazepine, in young and elderly subjects. , 1997, British journal of anaesthesia.

[45]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[46]  Lewis B. Sheiner,et al.  A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.

[47]  Jerome J. Schentag,et al.  Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers , 1997, Antimicrobial agents and chemotherapy.

[48]  N H Holford,et al.  The Target Concentration Approach to Clinical Drug Development , 1995, Clinical pharmacokinetics.

[49]  N. Holford,et al.  Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[50]  R. Larsson,et al.  A general model for time‐dissociated pharmacokinetic‐pharmacodynamic relationships exemplified by paclitaxel myelosuppression , 1998, Clinical pharmacology and therapeutics.

[51]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.

[52]  M Danhof,et al.  Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.

[53]  A Bye,et al.  Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate , 1996, Journal of clinical pharmacology.

[54]  L B Sheiner,et al.  Pharmacodynamic model of tolerance: application to nicotine. , 1988, The Journal of pharmacology and experimental therapeutics.

[55]  Carl Peck,et al.  An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.

[56]  J L Steimer,et al.  Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[57]  William J. Jusko,et al.  Second generation model for prednisolone pharmacodynamics in the rat , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[58]  M. Gibaldi,et al.  Drug distribution and pharmacologic effects , 1971 .